Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Cherry Hill, NJ
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Charlotte, NC
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Easley, SC
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Greenville, SC
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Spartanburg, SC
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Union, SC
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Richmond, VA
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Aalst,
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Aalst,
Click here to add this to my saved trials
Alpha-1 Carrier Genomics Study
Alpha-1 Carrier Genomics Study
Status: Enrolling
Updated:  1/26/2018
Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine
mi
from
Charleston, SC
Alpha-1 Carrier Genomics Study
Alpha-1 Carrier Genomics Study
Status: Enrolling
Updated: 1/26/2018
Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Jasper Summit Research, LLC
mi
from
Jasper, AL
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Jasper Summit Research, LLC
mi
from
Jasper, AL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
California Research Medical Group
mi
from
Fullerton, CA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
California Research Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Integrated Research Group
mi
from
Riverside, CA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Integrated Research Group
mi
from
Riverside, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Capital Allergy and Respiratory Disease Center
mi
from
Sacramento, CA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Capital Allergy and Respiratory Disease Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Institute of HealthCare Assessment, Inc.
mi
from
San Diego, CA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Institute of HealthCare Assessment, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Clinical Research of West Florida
mi
from
Clearwater, FL
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Clinical Research of West Florida
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Georgia Clinical Research
mi
from
Austell, GA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Georgia Clinical Research
mi
from
Austell, GA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Gwinnett Biomedical Research
mi
from
Lawrenceville, GA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Gwinnett Biomedical Research
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Veritas Clinical Specialities, LTD
mi
from
Topeka, KA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Veritas Clinical Specialities, LTD
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
American Health Research Inc.
mi
from
Charlotte, NC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
American Health Research Inc.
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
New Horizons Clinical Research
mi
from
Cincinnati, OH
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
New Horizons Clinical Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Sunstone Medical Research, LLC
mi
from
Medford, OR
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Clinical Research Institute of Southern Oregon, PC
mi
from
Medford, OR
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Clinical Research Institute of Southern Oregon, PC
mi
from
Medford, OR
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Allergy Associates Research Center
mi
from
Portland, OR
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Allergy Associates Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Upstate Pharmaceutical Research
mi
from
Greenville, SC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Upstate Pharmaceutical Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Greenville Pharmaceutical Research
mi
from
Greenville, SC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Greenville Pharmaceutical Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
South Carolina Pharmaceutical Research
mi
from
Spartanburg, SC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
South Carolina Pharmaceutical Research
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
CU Pharmacuetical Research
mi
from
Union, SC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
CU Pharmacuetical Research
mi
from
Union, SC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Baylor College of Medicine
mi
from
Houston, TX
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Central Texas Health Research
mi
from
New Braunfels, TX
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Central Texas Health Research
mi
from
New Braunfels, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
North Carolina Clinical Research
mi
from
Raleigh, NC
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
North Carolina Clinical Research
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Pulmonary Associates of Richmond, Inc
mi
from
Richmond, VA
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Pulmonary Associates of Richmond, Inc
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Pulmonary Associates, PA
mi
from
Phoenix, AZ
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Pulmonary Associates, PA
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated:  2/6/2018
Minnesota Lung Center
mi
from
Minneapolis, MN
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Status: Enrolling
Updated: 2/6/2018
Minnesota Lung Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Status: Enrolling
Updated:  2/6/2018
University of Colorado Hospital
mi
from
Aurora, CO
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Status: Enrolling
Updated: 2/6/2018
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated:  2/8/2018
GSK Investigational Site
mi
from
Madisonville, KY
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated: 2/8/2018
GSK Investigational Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated:  2/8/2018
GSK Investigational Site
mi
from
Charlotte, NC
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated: 2/8/2018
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated:  2/8/2018
GSK Investigational Site
mi
from
Spartanburg, SC
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated: 2/8/2018
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated:  2/8/2018
GSK Investigational Site
mi
from
Union, SC
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated: 2/8/2018
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated:  2/8/2018
GSK Investigational Site
mi
from
Tallinn,
28-day Repeat Dose Study of GSK573719
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD
Status: Enrolling
Updated: 2/8/2018
GSK Investigational Site
mi
from
Tallinn,
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Kaiser Permanente Riverside Medical Center
mi
from
Riverside, CA
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Kaiser Permanente Riverside Medical Center
mi
from
Riverside, CA
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
University of California, San Diego
mi
from
San Diego, CA
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Miami VA Healthcare System
mi
from
Miami, FL
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Miami VA Healthcare System
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Tampa General Hospital
mi
from
Tampa, FL
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated:  2/12/2018
Piedmont Hospital
mi
from
Atlanta, GA
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Status: Enrolling
Updated: 2/12/2018
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials